tDCS in the Management of Post-COVID Disorders

NCT ID: NCT06074848

Last Updated: 2024-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-25

Study Completion Date

2024-09-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Different physical and mental morbidities such as pain, fatigue, depressed mood and cognitive impairment can be triggered by coronavirus infection. Transcranial direct current stimulation (tDCS), an easy-to-apply, non-pharmacological and safe technique, has been used to attenuate these symptoms caused by other diseases, and, therefore, it is expected that it can also attenuate them when generated by COVID-19. It is known that the persistent inflammatory state observed after COVID-19 would be related to the progression of these negative symptoms. As non-invasive brain stimulation can also attenuate acute and persistent inflammation, it can be estimated that tDCS can be a useful tool to recover immune function and reduce post-COVID-19 morbidity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to investigate if Direct Current Electrical Stimulation (tDCS) associated with motor and/or cognitive training is capable of reducing neuropsychiatric symptoms, as well as immune changes induced in COVID-19.

Volunteers will be randomized and allocated into four groups (Fatigue; Pain; Cognitive deficit and Depressed mood) and each group will be divided into two subgroups: 1) real tDCS + motor or cognitive training; and, 2) sham tDCS + motor or cognitive training according to each outcome. The volunteers will be evaluated in two aspect: immunometabolic evaluation (i) and clinical assessment (ii). The measures will pe performed in three moments: baseline (session 1); 72 hours after the last intervention (session 12) and follow up - 15 days after the last intervention (session 13).

(i) The immunometabolic evaluation will start with the participant's blood collection, after fasting for 8-12 hours, without having practiced intense physical activity and without drinking alcohol in the 24 hours prior to the collect. The blood will be allocated in 10 vacutainer tubes of 5ml containing EDTA for plasma separation, in 2 dry vacutainer tubes of 5ml for serum separation and 1 vacutainer tube of 5ml containing fluoride. In particular, 1 dry tube must rest for 1h, for subsequent BDNF analysis. 2 serum tubes, 2 plasma tubes and 1 fluoride tube should be centrifuged at 3,500 rpm for 15 minutes at 4°C, and the samples should be stored at -80°C for later analysis and the other fresh plasma tubes used (up to 2 hours after collection) for whole blood and PBMC stimuli.

Stimulation of whole blood with LPS, culture of peripheral blood mononuclear cells (PBMC), assessment of oxidative stress, assessment of adenine and LPS purine levels in plasma, analysis of immunophenotyping and apoptosis by flow cytometry, assessment of expression of purinoreceptors, mitochondrial assays in monocytes and T lymphocytes, evaluation of the generation of reactive oxygen species and quantification of several mediators by ELISA.

(ii) The clinical assessment will be performed using the following outcome measures:

COVID clinical situation - IInitially, modules 1 and 2 of the Case Report Form - CRF (Pcovid frameost COVID-19 CRF) of the Pan American Health Organization (PAHO) will be completed. Where module 1 comprises demographic data and clinical information related to the acute episode of COVID-19 and module 2 includes questions related to vaccination, occupational and functional status of the volunteer.

Fatigue - The Modified Impact of Fatigue Scale (MFIS) contains 21 items that analyze cognitive, physical and psychosocial issues in relation to fatigue, assessing the impact that is caused in the patient's life.

Pain - Brief Pain Inventory (BPI) assesses pain severity, impact of pain on daily function, pain location, pain medications, and amount of pain relief in the last 24 hours and last week; Visual Analog Scale (VAS) consists of a ruler numbered from 0 to 10 and divided into three parts, light, moderate and severe, with visual aid to facilitate the measurement of the patient's pain intensity.

Cognitive deficit - Montreal Cognitive Assessment (MoCA) instrument that quickly identifies cognitive declines in patients; FAS Test is a Verbal Fluency Test - Phonological Fluency Test that assesses verbal learning and the ability to produce words verbally; Random Number Generator (RNG test) assesses language and executive function; Digit span that will be used to assess the ability to focus, maintain attention, and mental manipulation. In the follow up, the CFL-test will be added to a verbal fluency test.

Depressed mood - Hospital Anxiety and Depression Scale (HADS) measures symptoms of anxiety and depression and consists of 14 items, seven for the anxiety subscale (HADS-Anxiety) and seven for the depression subscale (HADS-Depression); Brunel Mood Scale (BRUMS) used to quickly measure the patient's mood state.

Level of physical activity - The short version of IPAQ will be performed to identify if the volunteer has a life with active physical activities. It makes it possible to estimate the weekly time used for physical activities.

Vital signs - at the end of the scales, the signs of each patient will be measured: blood pressure, heart rate, respiratory rate and peripheral O2 saturation, parameters used to verify the hemodynamic status of the volunteer.

State of strength and effort - the handgrip strength test and perception of effort performed with the dynamometer will be used, quantitatively indicating the muscle strength of the hand and forearm.

Exercise capacity - the functional capacity and aerobic resistance of the participant will be evaluated through the 6-minute walk test. The test measures the distance that the volunteer covers in a period of 6 minutes walking at a stable speed.

At the end, a questionnaire of adverse effects of the evaluation will be carried out, containing information regarding any discomfort felt during the evaluation.

The intervention process will be carried out with Transcranial Direct Current Stimulation which will be applied for 30 minutes (2 mA; 0.057 mA/cm²) during motor or cognitive training. For symptoms of pain and/or fatigue, the anode will be positioned in the area referring to the left primary motor cortex (C3, according to the EEG positioning system). For symptoms of depressed mood and/or cognitive impairment, the anode will be positioned in the area of the left dorsolateral prefrontal cortex (F3). In both situations, the cathode will be positioned in the contralateral supraorbital region. In sham tDCS, the same parameters and setup as the real stimulation will be used, however, the application time will be 30 seconds, but the electrodes will be maintained for 30 minutes.

In motor training, the treadmill training protocol will last a total of 30 minutes and will be carried out during the application of tDCS. After positioning the tDCS electrodes, a cardiac monitor will be positioned on the individual to control HR. Before starting the protocol on the treadmill, the values of the perceived exertion scale (Borg) and HR should be noted.

Initially, the target HR for each part of the intervention will be determined. The formula by Tanaka et al., (2001) will be used to determine the maximum HR, with maximum HR = 208 - (0.7\*age). For participants who use beta-blockers, the formula by Brawner et al., (2004) will be used, with maximum HR = 164 - (0.7\*age).

The initial five minutes will be a warm-up. To achieve this, the target HR must be maintained at 50-60% of the maximum HR. The speed of the treadmill must be adjusted to maintain the HR within the pre-established target range. At five minutes, the Borg scale values, treadmill speed and HR must be noted. The central 20 minutes will be considered as the main part. To achieve this, the target HR must be maintained at 64-76% of the maximum HR. If the participant chooses to stop the treadmill session, the treadmill must be turned off and the participant must remain seated until the end of the tDCS application.

For cognitive training, carried out during tDCS, an n-Back task will be performed online in PsyToolkit (https://www.psytoolkit.org/). For a benefit on working memory learning curves. Performed for the outcomes of cognitive impairment and depressed mood. During the test, the volunteer will have to indicate which letter was projected by the application two letters ago. The system will show one letter followed by another, the volunteer must press the "space" key on the computer keyboard when the letter that was shown in the two positions above reappears.

The study will be carried out simultaneously in two research centers in Brazil: Laboratory of Applied Neuroscience (LANA), Federal University of Pernambuco (UFPE), Pernambuco, Brazil and at the Department of Physical Education, Faculty of Science and Technology - Campus Presidente Prudente (FCT/UNESP), São Paulo, Brazil.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Long COVID

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pain/fatigue tDCS real

tDCS will be applied for 30 minutes (2 mA; 0.057 mA/cm²) during motor training. The anode will be positioned in the area referring to the left motor cortex (C3). The cathode will be positioned in the contralateral supraorbital region.

Motor Training: the participant will be positioned on the mat where the initial 5 minutes will be warmed up with the target heart rate maintained at 50-60% of the maximum heart rate. The treadmill speed must be adjusted to keep the HR within the pre-established target range. At 5 minutes, Borg scale values, treadmill speed and HR should be recorded. The central 20 minutes will be considered the main part. For this, the target HR must be maintained between 64-76% of the maximum HR. Every 5 minutes (minutes 10, 15, 20 and 25) the values of the Borg scale, treadmill speed and HR must be recorded. In the final 5 minutes, the target HR must be kept below 60% of the maximum HR. Totaling 30 minutes of training on the treadmill.

Group Type EXPERIMENTAL

Transcranial Direct Current Stimulation (tDCS)

Intervention Type DEVICE

tDCS deliver low-intensity electrical currents (2 mA) through electrodes placed on the scalp. It is used to influence brain function, modulating the neuronal activity in specific areas, in a non-invasive way, as the stimulation may not be perceived sensorially due to the low intensity. In some cases, it can provide mild tingling and bring minimal discomfort. It has the ability to increase or decrease the cortical excitability of neurons, influencing the polarization of neuronal membranes, with the anodal pole (positive) facilitating depolarization that results in increased neuronal excitability in the area, and the cathodal pole (negative) promoting a hyperpolarization of the neuronal resting membrane potential that reduces cortical excitability, used to inhibit activity in a particular cortical area.

Motor Training

Intervention Type BEHAVIORAL

Motor training will be performed on the treadmill with the speed respecting the limits of the patient's maximum heart rate. To determine the maximum heart rate, the calculation must be performed: maximum heart rate = 208 - (0.7\*age). For participants who use beta-blockers, the following formula will be used: maximum heart rate = 164 - (0.7\*age). Just for the arms of fatigue and pain.

Pain/fatigue tDCS sham

tDCS will be applied for 30 seconds (2 mA; 0.057 mA/cm²) during motor training. The anode will be positioned in the area referring to the left motor cortex (C3). The cathode will be positioned in the contralateral supraorbital region.

Motor Training: the participant will be positioned on the mat where the initial 5 minutes will be warmed up with the target heart rate maintained at 50-60% of the maximum heart rate. The treadmill speed must be adjusted to keep the HR within the pre-established target range. At 5 minutes, Borg scale values, treadmill speed and HR should be recorded. The central 20 minutes will be considered the main part. For this, the target HR must be maintained between 64-76% of the maximum HR. Every 5 minutes (minutes 10, 15, 20 and 25) the values of the Borg scale, treadmill speed and HR must be recorded. In the final 5 minutes, the target HR must be kept below 60% of the maximum HR. Totaling 30 minutes of training on the treadmill.

Group Type SHAM_COMPARATOR

Motor Training

Intervention Type BEHAVIORAL

Motor training will be performed on the treadmill with the speed respecting the limits of the patient's maximum heart rate. To determine the maximum heart rate, the calculation must be performed: maximum heart rate = 208 - (0.7\*age). For participants who use beta-blockers, the following formula will be used: maximum heart rate = 164 - (0.7\*age). Just for the arms of fatigue and pain.

Cognitive deficit and depressed mood tDCS real

tDCS will be applied for 30 minutes (2 mA; 0.057 mA/cm²) during cognitive training. For volunteers with symptoms of depressed mood and/or cognitive impairment, the anode will be positioned in the area of the left dorsolateral prefrontal cortex (F3) and cognitive training will be performed. The cathode will be positioned in the contralateral supraorbital region.

Cognitive Training: For cognitive training, performed during tDCS, a n-Back task will be performed online in the PsyToolkit (https://www.psytoolkit.org/). A previous study demonstrated the benefit of tDCS when combined with this cognitive training on working memory learning curves.

Group Type EXPERIMENTAL

Transcranial Direct Current Stimulation (tDCS)

Intervention Type DEVICE

tDCS deliver low-intensity electrical currents (2 mA) through electrodes placed on the scalp. It is used to influence brain function, modulating the neuronal activity in specific areas, in a non-invasive way, as the stimulation may not be perceived sensorially due to the low intensity. In some cases, it can provide mild tingling and bring minimal discomfort. It has the ability to increase or decrease the cortical excitability of neurons, influencing the polarization of neuronal membranes, with the anodal pole (positive) facilitating depolarization that results in increased neuronal excitability in the area, and the cathodal pole (negative) promoting a hyperpolarization of the neuronal resting membrane potential that reduces cortical excitability, used to inhibit activity in a particular cortical area.

Cognitive Training

Intervention Type BEHAVIORAL

an n-Back task will be performed online at PsyToolkit (https://www.psytoolkit.org/). Just for the arms of cognitive impairment and depressed mood.

Cognitive deficit and depressed mood tDCS sham

tDCS will be applied for 30 seconds (2 mA; 0.057 mA/cm²) during cognitive training. For volunteers with symptoms of depressed mood and/or cognitive impairment, the anode will be positioned in the area of the left dorsolateral prefrontal cortex (F3) and cognitive training will be performed. The cathode will be positioned in the contralateral supraorbital region.

Cognitive Training: For cognitive training, performed during tDCS, a n-Back task will be performed online in the PsyToolkit (https://www.psytoolkit.org/). A previous study demonstrated the benefit of tDCS when combined with this cognitive training on working memory learning curves.

Group Type SHAM_COMPARATOR

Cognitive Training

Intervention Type BEHAVIORAL

an n-Back task will be performed online at PsyToolkit (https://www.psytoolkit.org/). Just for the arms of cognitive impairment and depressed mood.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcranial Direct Current Stimulation (tDCS)

tDCS deliver low-intensity electrical currents (2 mA) through electrodes placed on the scalp. It is used to influence brain function, modulating the neuronal activity in specific areas, in a non-invasive way, as the stimulation may not be perceived sensorially due to the low intensity. In some cases, it can provide mild tingling and bring minimal discomfort. It has the ability to increase or decrease the cortical excitability of neurons, influencing the polarization of neuronal membranes, with the anodal pole (positive) facilitating depolarization that results in increased neuronal excitability in the area, and the cathodal pole (negative) promoting a hyperpolarization of the neuronal resting membrane potential that reduces cortical excitability, used to inhibit activity in a particular cortical area.

Intervention Type DEVICE

Motor Training

Motor training will be performed on the treadmill with the speed respecting the limits of the patient's maximum heart rate. To determine the maximum heart rate, the calculation must be performed: maximum heart rate = 208 - (0.7\*age). For participants who use beta-blockers, the following formula will be used: maximum heart rate = 164 - (0.7\*age). Just for the arms of fatigue and pain.

Intervention Type BEHAVIORAL

Cognitive Training

an n-Back task will be performed online at PsyToolkit (https://www.psytoolkit.org/). Just for the arms of cognitive impairment and depressed mood.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

non-invasive brain stimulation, neuroConn (Germany)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Long COVID-19 (\>3 months)
* The presence of at least one of the following symptoms, after diagnosed SARS-COV-2 infection:

Persistent pain Fatigue Depressed mood Cognitive impairment

Exclusion Criteria

* Hemodynamic instability
* Historic of use or abuse of drugs or alcohol
* Use of medications that may interfere with the study results (anti-inflammatories and antibiotics)
* Metallic implant in skull and face
* Implant in the central nervous system
* Pacemaker
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

São Paulo State University

OTHER

Sponsor Role collaborator

Universidade Federal de Pernambuco

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kátia Monte-Silva

Investigador principal

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Patrícia Lopes, graduation

Role: STUDY_CHAIR

Laboratory of Applied Neuroscience, Federal University of Pernambuco

Lívia Shirahige, PhD

Role: STUDY_CHAIR

Laboratory of Applied Neuroscience, Federal University of Pernambuco

Bárbara Sousa

Role: STUDY_CHAIR

Laboratory of Applied Neuroscience, Federal University of Pernambuco

Ana Cecília

Role: STUDY_CHAIR

Laboratory of Applied Neuroscience, Federal University of Pernambuco

Adriana Baltar, PhD

Role: STUDY_CHAIR

Laboratory of Applied Neuroscience, Federal University of Pernambuco

Rodrigo De Mattos, Master

Role: STUDY_CHAIR

Laboratory of Applied Neuroscience, Federal University of Pernambuco

Gabriel Barreto, Master

Role: STUDY_CHAIR

Laboratory of Applied Neuroscience, Federal University of Pernambuco

Fábio Santos de Lira, PhD

Role: STUDY_CHAIR

Department of Physical Education, Faculty of Science and Technology - Presidente Prudente Campus

Fabrício Oliveira Souto, PhD

Role: STUDY_CHAIR

Universidade Federal de Pernambuco

Kátia Monte-Silva, PhD

Role: STUDY_DIRECTOR

Laboratory of Applied Neuroscience, Federal University of Pernambuco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Applied Neuroscience Laboratory-LANA

Recife, Pernambuco, Brazil

Site Status RECRUITING

Department of Physical Education, Faculty of Science and Technology

Presidente Prudente, São Paulo, Brazil

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kátia Monte-Silva, PhD

Role: CONTACT

+55 81 988631322

Patrícia Lopes, graduation

Role: CONTACT

+55 81 999897661

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kátia Monte-Silva, PhD

Role: primary

+55 81 988631322

Patrícia Lopes, Graduation

Role: backup

+55 81 999897661

Fábio Santos de Lira, PhD

Role: primary

+351 911 901 861

Related Links

Access external resources that provide additional context or updates about the study.

https://pubmed.ncbi.nlm.nih.gov/24605122/

Choi, Hyo Jung, Dong Young Lee, et al. 2014. "A Normative Study of the Digit Span in an Educationally Diverse Elderly Population." Psychiatry Investigation 11 (1): 39-43.

https://pubmed.ncbi.nlm.nih.gov/35754396/

Dorneles, Gilson P., Paula C. Teixeira, et al. 2022. "Alterations in CD39/CD73 Axis of T Cells Associated with COVID-19 Severity." Journal of Cellula

https://observatorio.fm.usp.br/handle/OPI/48228

Lira, Pereira, and Guerra Minuzzi. "Functions in Adult Patients with Mild to Moderate SARS-CoV-2 Infections-A Protocol for an Observational Prospective Follow-Up Investigation: Fit-COVID-19." International Journal of High Risk Behaviors \& Addict. 2021

https://pubmed.ncbi.nlm.nih.gov/35980161/

Postiga, Isabelle A. L., Paula C., et al. "Systemic Redox Imbalance in Severe COVID-19 Patients." Cell Biochemistry and Function, August. 2022.

https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-1739816

Romão PR, Teixeira PC, Schipper L, et al. Viral load is associated with mitochondrial dysfunction and altered monocyte phenotype in acute severe SARS-CoV-2 infection. Int Immunopharmacol. 2022 Jul;108:108697. doi: 10.1016/j.intimp.2022.108697.

https://pubmed.ncbi.nlm.nih.gov/25797650/

Rossini, PM et al. 2015. "Non-Invasive Electrical and Magnetic Stimulation of the Brain, Spinal Cord, Roots and Peripheral Nerves: Basic Principles and Procedures for Routine Clinical and Research Application. An Updated Report from an IFCN Committee

https://pubmed.ncbi.nlm.nih.gov/28446889/

Scarpina, Federica, and Sofia Tagini. 2017. "The Stroop Color and Word Test." Frontiers in Psychology 8 (April): 557.

https://pubmed.ncbi.nlm.nih.gov/34543980/

Teixeira PC, Dorneles GP, Santana Filho PC, et al. Increased LPS levels coexist with systemic inflammation and result in monocyte activation in severe COVID-19 patients. Int Immunopharmacol. 2021 Nov;100:108125. doi: 10.1016/j.intimp.2021.108125.

https://pubmed.ncbi.nlm.nih.gov/33774378/

Versace, Viviana, Luca Sebastianelli, et al. 2021. "Intracortical GABAergic Dysfunction in Patients with Fatigue and Dysexecutive Syndrome after COVID-19." Clinical Neurophysiology: Official Journal of the Int Federation of Clinical Neurophysiol

https://doi.org/10.1038/s41392-020-00243-2

Yang, L., Liu, S., Liu, J. et al. COVID-19: immunopathogenesis and Immunotherapeutics. Sig Transduct Target Ther 5, 128 (2020)

https://cdn.who.int/media/docs/default-source/3rd-edl-submissions/who_crf_postcovid_feb9_2021.pdf

Organização Pan-Americana da Saúde. Plataforma Clínica Global da COVID-19 Ficha Clínica (Case Report Form - CRF) para quadro pós-COVID (Post COVID-19 CRF). OPAS-W/BRA/PHE/COVID-19/21-0025 (2021).

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

tDCS_COVID

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Brain Stimulation for Mild Traumatic Brain Injury
NCT02292589 ACTIVE_NOT_RECRUITING PHASE2